Fatty Liver Disease and Multi-System Complications
joint with Hepatobiliary Cancers: Pathobiology and Translational Advances
Scientific Organizers: Jay D. Horton, Morris J. Birnbaum and Hannele Yki-Järvinen
Date: March 21 - 24, 2021
Location: Fairmont Hotel Vancouver, Vancouver, BC, Canada
Nonalcoholic fatty liver disease (NAFLD) has risen worldwide in parallel with the obesity epidemic; however, there still are no approved therapies. The more advanced form of the disease, non-alcoholic steatohepatitis (NASH), is associated with progressive fibrosis and an increased risk of hepatocellular carcinoma (HCC). Significant advances have been made our understanding of the alterations in lipid and glucose metabolism that lead to fat accumulation in liver and an understanding of the underlying molecular pathways that mediate these changes is starting to emerge. The past decade, genetic studies have identified new proteins that participate not only in the development of hepatic steatosis, but also disease progression to NASH, cirrhosis, and HCC. Therefore, the goals of this conference are to: 1) Explore the genetic contributions to NAFLD and discuss how these crucial discoveries can be used to define the sequence of events that result in NASH and cirrhosis; 2) Clarify the key molecular events in NAFLD and NASH, focusing on pathways that might provide therapeutic opportunities; and 3) Highlight emerging therapies for NASH. The conference comes at an opportunistic time as several clinical trials should have new results that will permit us to refine research strategies for the future.
Registration opens in January 2020